History

GHRP-2 grew out of Cyril Y. Bowers' growth-hormone-secretagogue research at Tulane University, which built iteratively on earlier GHRPs (GHRP-6, GHRP-1). Per a 2004 Drugs R&D development record, the peptide series was developed by Polygen (Germany) and Tulane; Wyeth ran US Phase II trials for GH deficiency that were later discontinued, while Kaken Pharmaceutical developed it in Japan as a diagnostic and short-stature candidate. Foundational human studies ran from the late 1990s through the 2007 adult diagnostic validation. The therapeutic short-stature programs were ultimately abandoned.

GHRP-2 is one of those compounds with a genuine, narrow medical use that has been stretched far past what the evidence supports. In Japan it is an approved diagnostic: a single dose provokes a measurable spike in growth hormone, which helps doctors test for growth hormone deficiency. Online, it is sold as a “research chemical” and promoted for muscle gain, fat loss, recovery, and anti-aging — none of which is backed by outcome trials. This profile separates the two.

What it is

GHRP-2, also called pralmorelin, is a synthetic hexapeptide — a chain of six amino acids. Its molecular formula is C45H55N9O6, with a molecular weight of about 817.97 g/mol (PubChem CID 5493556, the acetate salt; free pralmorelin is CID 6918245). Its sequence includes several D-amino acids and an unnatural naphthylalanine residue, which make it resistant to the enzymes that would normally break down a peptide and give it high affinity for its target receptor.

That target is the growth hormone secretagogue receptor type 1a (GHS-R1a) — better known as the ghrelin receptor. It sits on the growth-hormone-producing cells of the pituitary and in the hypothalamus. By activating this receptor, GHRP-2 mimics ghrelin, the so-called hunger hormone, and amplifies the body’s natural pulses of growth hormone release. It works alongside the body’s own growth-hormone-releasing hormone and partly overrides the braking signal from somatostatin.

Importantly, GHRP-2 is not specific to growth hormone. It also modestly raises ACTH and cortisol, nudges prolactin upward, and stimulates appetite through the same ghrelin pathways. Those off-target effects are documented in human pharmacology studies and matter for any honest discussion of its risks.

The claims

There is one legitimate, studied use: as a growth-hormone provocation test. A single intravenous dose produces a reproducible growth hormone peak, which clinicians can use to test for deficiency without the hypoglycemia risk of the older insulin tolerance test. This is the approved indication in Japan.

Beyond that, the picture splits sharply. GHRP-2 was investigated decades ago as a treatment for growth hormone deficiency and short stature in children, and as an appetite stimulant. Those programs were largely abandoned.

The gray-market claims — muscle gain, fat loss, anti-aging, better sleep, faster recovery, injury healing — are not supported by any outcome trials. One vendor has cited a “Phase III randomized placebo-controlled study for age-related changes in form, function and quality of life,” but no such trial could be found on ClinicalTrials.gov or in the peer-reviewed literature. Treat that as unverified marketing copy.

The evidence

The strongest human data concern the diagnostic use. A 2007 study by Chihara and colleagues in the European Journal of Endocrinology tested 77 healthy subjects and 58 patients with confirmed growth hormone deficiency, using a single 100 µg intravenous dose. It established a peak growth-hormone cutoff for diagnosing deficiency in adults (about 15 µg/L; the same threshold recalibrated to a recombinant WHO standard works out to about 9 µg/L — a recalibration, not a separate “severe” cutoff). This work underpins the Japanese approval.

On endocrine pharmacology, a 1997 study by Arvat and colleagues in Peptides gave GHRP-2 to six healthy young adults. It produced a larger growth hormone response than growth-hormone-releasing hormone, along with comparable rises in ACTH and cortisol and a mild prolactin increase — the clearest documentation of the off-target hormonal effects. The sample was tiny and the endpoints were hormonal, not clinical.

On appetite, a 2005 crossover study by Laferrère and colleagues in the Journal of Clinical Endocrinology and Metabolism infused GHRP-2 into seven lean healthy men and found food intake rose by about 36% versus saline, with a clear growth hormone rise. Again: very small, acute, and a surrogate endpoint.

The therapeutic studies in growth-hormone-deficient children are the most telling. A 1998 Phase I study (10 children) characterized the growth hormone response and a short half-life. An 8-month study of six children that same year found dose-dependent overnight growth hormone and faster growth velocity during treatment — but IGF-I and IGFBP-3 did not increase, there was no control group, and it was open-label. A 12-month study of oral GHRP-2 in 10 children found increased appetite in seven of them during the first six months, but no statistically significant change in BMI. Per the 2004 Drugs R&D record, the US Phase II program for growth hormone deficiency (run by Wyeth) appears to have been discontinued.

Animal pharmacology — sponsored by Kaken, the Japanese developer — showed that GHRP-2 released growth hormone more potently than growth-hormone-releasing hormone in rats and dogs and was less suppressible by somatostatin. That is mechanistically supportive but no substitute for human outcome data.

What is missing is the most important part. There are no replicated randomized controlled trials with hard endpoints — body composition, strength, fracture, frailty, function, or mortality. The therapeutic human trials are small (single-digit participant counts), old, often uncontrolled, and built on surrogate markers. There is also a conflict-of-interest signal worth naming: the discoverer is an author on much of the foundational human work, and the animal pharmacology was industry-sponsored.

That is why the overall evidence grade here is Preliminary human. Real human pharmacodynamic data exist, so this is well past “animal only” or “theoretical.” But only the diagnostic use approaches established status. The therapeutic and anti-aging claims sit much closer to having no credible evidence.

Safety and side effects

At single, diagnostic doses, GHRP-2 was generally well tolerated in published studies. The documented effects are the ones you would expect from its mechanism: increased appetite, and transient, non-specific rises in ACTH, cortisol, and prolactin (Arvat 1997). In the pediatric treatment studies, appetite rose without a significant change in BMI, and no toxicities were observed over eight months in six children — but those samples are far too small to establish safety.

Longer-term concerns are largely theoretical because they have not been well studied in humans. Sustained elevation of growth hormone and IGF-1 carries the familiar growth-hormone-axis risks: insulin resistance and glucose changes, fluid retention, carpal-tunnel-type symptoms, and joint problems. Repeated stimulation of cortisol and prolactin adds further uncertainty. Chronic, unsupervised use — the gray-market reality — has essentially no controlled long-term safety data behind it. On top of that, product sold outside an approved supply chain carries real purity and identity risks that have nothing to do with the molecule itself.

Legal and regulatory status

In the United States, GHRP-2 is not approved for any use and never went through FDA approval. The FDA has issued warning letters citing it, stating that drug products compounded with GHRP-2 are not eligible for the relevant compounding exemption because it lacks a USP monograph, is not a component of an approved drug, and is not on the bulk substances list. Under the FDA’s earlier interim compounding framework, GHRP-2 was treated as Category 3 (nominated without adequate support or with safety concerns). The FDA discontinued that Category 2/3 labeling scheme in January 2025.

There is an active 2026 FDA review of peptide compounding, with a PCAC meeting scheduled for July 2026 covering about a dozen peptides. GHRP-2 is not among the peptides on that agenda — that list includes compounds such as BPC-157, KPV, TB-500, MOTS-C, and others. So while the regulatory landscape for peptides is shifting broadly, that particular review does not directly cover GHRP-2. Anyone needing current status should check FDA postings directly.

In Japan, GHRP-2 has its only approval, marketed by Kaken Pharmaceutical as a single-dose intravenous growth-hormone-stimulation diagnostic under the brand “GHRP Kaken.” Many secondary and vendor sources state an October 2004 approval date, but the contemporaneous 2004 Drugs R&D record describes it as then awaiting approval, so the exact date is not firmly confirmed.

For athletes, GHRP-2 is prohibited by the World Anti-Doping Agency at all times, in and out of competition, under Section S2 (peptide hormones, growth factors, and related substances), in the growth-hormone-releasing-factors subsection. It is named explicitly and is a non-specified substance.

Bottom line

GHRP-2 reliably does one thing in humans: it provokes a measurable growth hormone pulse. That property has earned it a legitimate, approved place as a diagnostic test in Japan, and the human pharmacology behind that is solid. Everything else is thinner than the marketing suggests. The therapeutic studies are small, old, and largely uncontrolled; the programs that tried to turn it into a treatment for short stature were abandoned; and the popular claims about muscle, fat loss, and anti-aging rest on no outcome trials at all. It is banned in sport, not approved in the US, and sold in an unregulated market with real purity risks. The honest summary is that GHRP-2 has a narrow proven use and a wide, unproven reputation.

GHRP-2: A diagnostic peptide with thin therapeutic evidence